Publications by authors named "David Geho"

Claim this Profile
E
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, Alwin D R Huitema, Vaios Karanikas, David Geho

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
Hua Zhong, Gong Chen, Lori Jukofsky, David Geho, Sung Won Han

Br J Haematol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, Vaios Karanikas, Morten Mau-Sorensen, David Geho

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein pathway analysis in Clinical Proteomics using protein microarrays.
David H Geho, Virginia Espina, Julia Wulfkuhle, Emanuel F Petricoin, Lance A Liotta

Drug Discov Today Technol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Smith, Tom Nevins, David Geho

Clin Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
Isabelle Ray-Coquard, Jean-Yves Blay, Antoine Italiano, Axel Le Cesne, Nicolas Penel, David Geho

Lancet Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.
Virginia Espina, Kirsten H Edmiston, Michael Heiby, Mariaelena Pierobon, Manuela Sciro, David H Geho

Mol Cell Proteomics· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.
Alessandra Luchini, David H Geho, Barney Bishop, Duy Tran, Cassandra Xia

Nano Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorescence-based analysis of cellular protein lysate arrays using quantum dots.
David H Geho, J Keith Killian, Animesh Nandi, Johanne Pastor, Prem Gurnani

Methods Mol Biol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laser-capture microdissection.
Virginia Espina, Julia D Wulfkuhle, Valerie S Calvert, Amy VanMeter, Weidong Zhou, David H Geho

Nat Protoc· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanotechnology in clinical proteomics.
David H Geho, Alessandra Luchini, Enrico Garaci, Claudio Belluco, Emanuel Petricoin

Nanomedicine (Lond)· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physicochemically modified silicon as a substrate for protein microarrays.
A Jasper Nijdam, Mark Ming-Cheng Cheng, David H Geho, Roberta Fedele, Paul Herrmann

Biomaterials· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots.
Thomas J Fountaine, Stephen M Wincovitch, David H Geho, Susan H Garfield, Stefania Pittaluga

Mod Pathol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of proteomics in personalized medicine.
David H Geho, James N Cooper, Virginia Espina, Enrico Garaci, Emanuel F Petricoin Rd

Per Med· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionation of serum components using nanoporous substrates.
David Geho, Mark Ming-Cheng Cheng, Keith Killian, Mark Lowenthal, Sally Ross

Bioconjug Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis.
Ramaprasad Srinivasan, Jasmine Daniels, Vincent Fusaro, Andreas Lundqvist, Jonathan K Killian, David Geho

Exp Hematol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoparticles: potential biomarker harvesters.
David H Geho, Clinton D Jones, Emanuel F Petricoin, Lance A Liotta

Curr Opin Chem Biol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The amplified peptidome: the new treasure chest of candidate biomarkers.
David H Geho, Lance A Liotta, Emanuel F Petricoin, Weidong Zhao, Robyn P Araujo

Curr Opin Chem Biol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype.
Nadeem Hussain, Martha Quezado, Marjan Huizing, David Geho, James G White

Clin Gastroenterol Hepatol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays.
David Geho, Nicholas Lahar, Prem Gurnani, Michael Huebschman, Paul Herrmann

Bioconjug Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiological mechanisms of tumor-cell invasion and migration.
David H Geho, Russell W Bandle, Timothy Clair, Lance A Liotta

Physiology (Bethesda)· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathology of the future: molecular profiling for targeted therapy.
Virginia Espina, David Geho, Arpita I Mehta, Emanuel F Petricoin, Lance A Liotta

Cancer Invest· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities for nanotechnology-based innovation in tissue proteomics.
David H Geho, Nicholas Lahar, Mauro Ferrari, Emanuel F Petricoin, Lance A Liotta

Biomed Microdevices· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum proteomics in cancer diagnosis and management.
Kevin P Rosenblatt, Peter Bryant-Greenwood, J Keith Killian, Arpita Mehta, David Geho

Annu Rev Med· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blasting into the microworld of tissue proteomics: a new window on cancer.
David H Geho, Emanuel F Petricoin, Lance A Liotta

Clin Cancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis